{
    "name": "ansuvimab",
    "comment": "Rx",
    "other_names": [
        "Ebanga",
        "ansuvimab-zykl"
    ],
    "classes": [
        "Monoclonal Antibodies"
    ],
    "source": "https://reference.medscape.com/drug/ebanga-ansuvimab-4000154",
    "pregnancy": {
        "common": [
            null,
            "Data from clinical trial demonstrate a high rate maternal and fetal/neonatal morbidity in treated pregnant females with ",
            "Data are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal/fetal outcome",
            "Animal reproduction studies have not been conducted",
            "Human monoclonal antibodies cross the placenta; therefore, monoclonal antibodies are potentially transferred from mother to fetus",
            "Lactation H3",
            "CDC recommends patients with confirmed ",
            "No data are available on presence in human or animal milk, effects on breastfed infants, or effects on milk production",
            "Maternal IgG is known to be present in human milk"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation H3"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [],
            "specific": [
                {
                    "type": "Hypersensitivity reactions",
                    "description": [
                        "Hypersensitivity reactions, including infusion-associated events, have been reported",
                        "These may include acute, life-threatening reactions during and after infusion",
                        "Monitor for signs and symptoms (eg, hypotension, chills, elevation of fever) during and following infusion",
                        "Infusion rate may be slowed or interrupted if any signs of infusion-associated events or other adverse events develop",
                        "Discontinue infusion immediately if severe or life-threatening reaction occurs and administer appropriate emergency care"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Avoid coadministration of live vaccine during treatment",
                        "Potential for monoclonal antibodies to inhibit replication of live vaccine virus indicated for prevention of ",
                        "Zaire ebolavirus",
                        " infection and possibly reduce vaccine efficacy",
                        "Follow current immunization guidelines for interval needed between monoclonal antibodies and administering live vaccine"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "axicabtagene ciloleucel",
            "description": {
                "common": "ansuvimab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "brexucabtagene autoleucel",
            "description": {
                "common": "ansuvimab, brexucabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ciltacabtagene autoleucel",
            "description": {
                "common": "ansuvimab, ciltacabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "idecabtagene vicleucel",
            "description": {
                "common": "ansuvimab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lisocabtagene maraleucel",
            "description": {
                "common": "ansuvimab, lisocabtagene maraleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tisagenlecleucel",
            "description": {
                "common": "ansuvimab, tisagenlecleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "efgartigimod alfa",
            "description": {
                "common": "efgartigimod alfa will decrease the level or effect of ansuvimab by  receptor binding competition. Use Caution/Monitor. Coadministration of efgartigimod with medications that bind to the human neonatal Fc receptor may lower systemic exposures and effectiveness of such medications. Closely monitor for reduced effectiveness of medications that bind to the human neonatal Fc receptor. If long-term use of such medications is essential, consider discontinuing efgartigimod and using alternative therapies."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isavuconazonium sulfate",
            "description": {
                "common": "ansuvimab and isavuconazonium sulfate both decrease  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ublituximab",
            "description": {
                "common": "ublituximab and ansuvimab both increase  immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Owing to potential additive immunosuppressive effects, consider duration of effect and mechanism of action of these therapies if coadministered"
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Diarrhea",
            "percent": "40"
        },
        {
            "name": "Pyrexia",
            "percent": "40"
        },
        {
            "name": "Abdominal pain",
            "percent": "40"
        },
        {
            "name": "Vomiting",
            "percent": "40"
        },
        {
            "name": "Creatinine",
            "percent": "1.8"
        },
        {
            "name": "x ULN or",
            "percent": "1.5"
        },
        {
            "name": "x baseline",
            "percent": "27"
        },
        {
            "name": "Pyrexia",
            "percent": "17"
        },
        {
            "name": "Potassium",
            "percent": "6.5"
        },
        {
            "name": "high",
            "percent": "15"
        },
        {
            "name": "mmol",
            "percent": "5"
        },
        {
            "name": "L",
            "percent": "13"
        },
        {
            "name": "AST",
            "percent": "5"
        },
        {
            "name": "x ULN",
            "percent": "12"
        },
        {
            "name": "ALT",
            "percent": "9"
        },
        {
            "name": "x ULN",
            "percent": "9"
        },
        {
            "name": "Tachycardia",
            "percent": "8"
        },
        {
            "name": "Diarrhea",
            "percent": "8"
        },
        {
            "name": "Vomiting",
            "percent": "125"
        },
        {
            "name": "Hypotension",
            "percent": "7"
        },
        {
            "name": "Sodium",
            "percent": "6"
        },
        {
            "name": "low",
            "percent": "2.5"
        },
        {
            "name": "mmol",
            "percent": "6"
        },
        {
            "name": "L",
            "percent": "154"
        },
        {
            "name": "Tachypnea",
            "percent": "5"
        },
        {
            "name": "Potassium",
            "percent": "5"
        },
        {
            "name": "low",
            "percent": "3"
        },
        {
            "name": "mmol",
            "percent": null
        },
        {
            "name": "L",
            "percent": null
        },
        {
            "name": "Sodium",
            "percent": null
        },
        {
            "name": "high",
            "percent": null
        },
        {
            "name": "mmol",
            "percent": null
        },
        {
            "name": "L",
            "percent": null
        },
        {
            "name": "Chills",
            "percent": null
        },
        {
            "name": "Hypoxia",
            "percent": null
        }
    ]
}